RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2015 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will present a company overview at the Stifel 2015 Healthcare Conference on Tuesday, November 17 at 10:15 a.m. EST at the New York Palace Hotel in New York City.

About G1 Therapeutics, Inc.

G1 Therapeutics is a clinical-stage oncology company developing novel, small-molecule therapies that address significant unmet needs in patients with cancer. The company is advancing G1T28, a first-in-class drug candidate, and G1T38, a potential best-in-class compound, in multiple oncology indications. G1 is privately held and based in Research Triangle Park, NC.

Visit www.g1therapeutics.com for more information.

CONTACT: Mark Velleca, MD, PhD
         G1 Therapeutics
         919-213-9838
         mvelleca@g1therapeutics.com
         
         Media:
         Laura Bagby
         6 Degrees Communications
         312-448-8098
         lbagby@6degreespr.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.